Background: Pituitary carcinoma (PC) is an aggressive neuroendocrine tumor diagnosed when a pituitary 28 adenoma (PA) becomes metastatic. PCs are typically resistant to therapy and frequently recur. Recently, 29 treatment with temozolomide (TMZ) has shown promising results, although the lack of prospective trials 30 limits accurate assessment. Methods: We describe a single-center experience in managing PC over a [22][23][24][25][26][27][28][29][30][31] year period and review previously published PC series. Results: 17 patients were identified. Median age 32 at PC diagnosis was 44 years (range 16-82), and the median PA-to-PC conversion time was 5 years (range 33 1-29). Median follow-up was 28 months (range 8-158) with 7 deaths. Most PC were hormone-positive 34 based on immunohistochemistry (n=12): ACTH (n=5), PRL (n=4), LH/FSH (n=2), GH (n=1). All patients 35 underwent at least one resection and one course of radiation after PC diagnosis. Immunohistochemistry 36 showed high Ki-67 labeling index (>3%) in 10/15 cases. Eight patients (47%) had metastases only to the 37 CNS, and 6 (35%) had combined CNS and systemic metastases. The most commonly used chemotherapy 38 was TMZ, and TMZ-based therapy was associated with the longest period of disease control in 12 (71%) 39 cases, as well as the longest period from PC diagnosis to first progression in 8 (47%) cases. The 2, 3 and 40 5-year survival rate of the entire cohort was 71%, 59% and 35%, respectively. All patients surviving >5 41 years were treated with TMZ-based therapy. Conclusions: PC treatment requires a multidisciplinary 42 3 approach and multimodality therapy including surgery, radiation and chemotherapy. TMZ-based therapy 43 was associated with higher survival rates and longer disease control. 44 45 Precis 46 We describe 17 PC patients who were diagnosed and treated at MDACC over a 22-year period. 47 
We have found that TMZ-based therapy correlated with longer disease control and higher 48 survival rate. 49 50 Introduction: 51 Pituitary carcinoma (PC) is a rare and aggressive neuroendocrine tumor (NET) accounting for 52 approximately 0.1% of all pituitary neoplasms. 1 The diagnosis is established after a pituitary 53 adenoma (PA) becomes metastatic. [2] [3] [4] Although metastases along the neuro-axis are more 54 frequently observed, spread outside the CNS is also seen. The typical PA to PC latency period is 55 several years, and little is known of the drivers for dissemination. Although p53 expression and 56 Ki-67 labeling index correlate well with the degree of peritumoral invasion and aggressive 57 behavior in PA, no specific histological or molecular markers are required to diagnose PC. 3, 5 The 58 management is challenging and a combination of surgical resection and/or radiation therapy is 59 typically recommended, with chemotherapy often used when surgery and radiation are not 60 possible or were previously unsuccessful. Nevertheless, response to standard treatment is 61 usually transient and PC recurrence is common, with a reported median overall survival (OS) of 62 1 year. 1,6 Improved outcome has been recently reported with the use of chemotherapy in 63 4 recurrent pituitary neuroendocrine tumors, 1,7 especially temozolomide (TMZ) 8-18 as a single 64 agent, in combination with capecitabine 19 or concurrently with radiotherapy 20,21 . Recent 65 practice guidelines for the management of aggressive pituitary tumors and PC have 66 recommended temozolomide as first line chemotherapy. 22 Here we summarize a 22-year 67 single-center experience treating newly diagnosed and recurrent PC, with an emphasis on the 68 use of TMZ-based therapy. 69 70 Methods: 71 We conducted a retrospective review of all adult PC patients included in the University of Texas The median PA to PC time to transformation (TTT) was 5 years (range 1-29 years, Table 1 ). One 100 patient was diagnosed simultaneously with PA and metastatic disease (de novo PC). Among the 101 IHC hormone-positive subtypes, ACTH-PC had the longest median TTT (5 years, range 2-29), 102 followed by PRL-PC (4 years, range 2-12 years), LH/FSH-PC (3 years, range 2-4 years) and GH-PC 103 (2 years). The median TTT of NC-PC was 9 years (range 1-15 years). (Table 1) .
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• Treatment modalities and outcome 151 The majority of patients received multimodality therapy. TMZ was the most frequently prescribed chemotherapy in this series (Table 1) , and it was used 177 in all PC subtypes: NC= 5/5; ACTH= 4/5; PRL= 3/4; LH/FSH= 1/2; GH= 1/1. TMZ was used for 178 newly diagnosed PC as monotherapy (n=4), concurrently with radiotherapy (n=2) and 179 immediately following radiotherapy (n=2). The most common TMZ scheduling and dosage was 180 150mg/m2 for 5 days on a 28-day cycle, for 12 months (n=6). TMZ was also used for recurrent 181 PC in 7 patients; it was given as monotherapy (n=5), combined with capecitabine (n=2; 182 CAPTEM: capecitabine 1200 mg/m2/day in divided doses twice daily, days 1 to 14, and TMZ 183 150-200 mg/m2/day in divided doses twice daily, days 10 to 14 of a 28-day cycle, for a total of 6 184 cycles) 11 , or concurrently with radiotherapy (n=1; TMZ 75 mg/m2 daily for 42 days combined 185 with radiation 5 days a week for 6 weeks). Table 1 ). The median follow-up after PC diagnosis was 227 2 years (range 1-13 years). The 2-, 3-and 5-yearsurvival rates for the entire cohort were 71% 228 (n=12), 59% (n=10), and 35% (n=6), respectively. Of the patients who were alive at least 5 years 229 from diagnosis, 2 patients (one NC-PC, one ACTH-PC, both still alive) survived more than 10 230 years and all 5 had received treatment with TMZ-based therapy (Table 1) 244 year OS rate 71%, 3-year OS rate 59%, 5-year OS rate 35%), compared with previous reports in 245 the literature (Table 2) The Ki-67 labeling index was assessed in the sellar tumor in the majority of our patients (n=15) 286 and, before the PC diagnosis was established, it was high (more than 3%) in 67% of them. The The rationale for the use of TMZ in PC is supported by several clinical and pharmacological 295 studies in neuroendocrine and primary brain tumors, indicating its excellent blood-brain barrier 296 penetration, in addition to its homogenous distribution in CNS and extra-CNS tissues. 12 in patients with high expression have been described. 35 Therefore, a trial of therapy with TMZ 317 may be warranted regardless of MGMT status, particularly if other treatment options have 318 been exhausted. 319 Further reports described the effective use of TMZ combined with capecitabine in recurrent 320 and metastatic PNETs 11,12,21,36-38 . The addition of capecitabine to TMZ (CAPTEM) is based on the 321 theory that sequential pretreatment with capecitabine may potentiate the cytotoxicity of TMZ 322 by synergistically depleting thymidine, leading to apoptosis. 11,28 A recent randomized Phase II 323 study has shown improved PFS and OS of capecitabine in combination with TMZ compared to 324 TMZ alone in advanced pancreatic NETs; 39 however, this has not been tested in PCs and 325 whether CAPTEM is superior to TMZ alone in this patient population remains unknown. 326 Potential benefits of using combined therapy must be carefully weighed against the potential 327 for added toxicities. In our series, the use of CAPTEM therapy in patients with previous 328 progression after TMZ monotherapy was limited to 3 cases, and definitive conclusions about 329 the benefit of CAPTEM in the setting of TMZ failure cannot be drawn. 330 In our patient cohort, we observed a longer median time between PC diagnosis and first PC 331 recurrence in patients treated with upfront TMZ-based therapy (30 months) compared with 332 patients treated with other lines of upfront therapy that was not TMZ-based (10 months), 333 although the low number of patients and the potential bias inherent in retrospective series 334 limits generalization of the validity of these results. Our results are also superior to those 335 previously reported in the literature (Table 2) ; this includes results from a contemporary study 336 in which TMZ was commonly prescribed, and which reported that 42.5% of PC patients were 337 deceased with median follow-up of 12 months. 40 Nevertheless, we are unable to confirm 338 whether the favorable outcome seen with TMZ is due to "first therapy effect", when the 339 longest PFS is usually seen, whether it is related to higher TMZ efficacy or, more likely, whether 340 it is a combination of both. 341 Radiotherapy with concurrent TMZ was completed in 3 patients, which was then followed by 342 cisplatin (n=1), TMZ (n=1) and capecitabine plus TMZ (n=1). Two of these patients had disease 343 control for more than 2 years, and all 3 patients survived for at least 3 years. This is in 344 agreement with a recent European survey which showed that concurrent TMZ and RT was 345 associated with increased response rate compared to TMZ alone. 40 The longer survival rates in 346 our cohort may be correlated to the multimodality approach and/or TMZ use, especially 347 considering that all long-term (>5 years) survivors were treated with TMZ-based therapy. 348 This study has the limitations typical of an observational retrospective study, including the small 349 cohort and single-center setting. Therefore, we are unable to draw any comparative statistical 
